PharmatrophiX — Aided by C2N Diagnostics — Finds That Its Small-Molecule Drug LM11A-31 Blocked the Rise of an Alzheimer's Disease Tau Pathology Biomarker

New Phase 2a analysis presented at the Clinical Trials on Alzheimer's Disease conference shows LM11A-31 prevented the increase of a biomarker associated with pathological neurofibrillary “tau” tangles

MENLO PARK, California and ST. LOUIS, Missouri (November 18, 2026) — PharmatrophiX, a privately-held, clinical-stage biopharmaceutical company pioneering the development of disease-modifying drugs targeting neurodegenerative diseases, and C2N Diagnostics, LLC, a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced new findings for Alzheimer’s disease patients from additional analysis of the Phase 2a clinical trial of PharmatrophiX’s LM11A-31, an orally administered small-molecule drug targeting the p75 neurotrophin receptor.

The analysis, jointly conducted with C2N Diagnostics using its proprietary biomarker technology, found that the higher dose of PharmatrophiX’s lead candidate, LM11A-31, significantly blocked the expected increase in levels of eMTBR-tau243 measured in the cerebrospinal fluid (CSF). eMTBR-tau243 is a core biomarker associated with neurofibrillary tangles comprised of intracellular aggregates of hyperphosphorylated tau protein that accumulate in the brain, contributing to one of the most damaging processes in Alzheimer’s disease.

“These findings provide additional encouraging evidence that LM11A-31 is acting on the underlying biology that drives Alzheimer’s disease,” said Frank M. Longo, MD, PhD, Co-Founder of PharmatrophiX. “Previous research has shown that eMTBR-tau243 begins to increase just before the time cognitive symptoms emerge and continues to rise as the disease progresses. Seeing this same pattern in our placebo group, which matched the findings of prior studies, while finding that LM11A-31 significantly prevented the increase, is particularly exciting and further strengthens our confidence in the drug’s potential to address a key feature of Alzheimer’s disease. We especially appreciate the opportunity to benefit from C2N’s expertise in both its biopharma research services and its analytic work that resulted in this jointly produced analysis.”

C2N and PharmatrophiX researchers worked together to analyze eMTBR-tau243 in CSF samples from 147 participants in PharmatrophiX’s previously reported 26-week Phase 2a placebo-controlled randomized clinical trial of LM11A-31 that Nature Medicine published. Subjects in the clinical trial were diagnosed as having mild-to-moderate Alzheimer’s disease. The analysis included 55 participants receiving a placebo, 46 receiving 200 mg of LM11A-31 twice daily and 46 receiving 400 mg twice daily. 

The joint research team found that eMTBR-tau243 levels:

  • increased by an annualized median of 25.92% in study participants receiving a placebo;

  • increased 10.90% for participants receiving the lower dose of LM11A-31 (200 mg twice daily); and

  • decreased by 2.10% for participants receiving the higher dose (400 mg twice daily), meaning the expected increase was entirely prevented.

The difference between the placebo and higher-dose group was statistically significant.

At the beginning of the trial, eMTBR-tau243 levels were also significantly associated with other established measures of Alzheimer's disease, including biomarkers linked to amyloid and tau protein buildup, damage to brain cells and their connections, and cognitive performance. These findings further support the potential of eMTBR-tau243 as a tool for tracking Alzheimer's-related changes in the brain and evaluating how experimental treatments may affect the disease's underlying biology.

PharmatrophiX says the findings add to a growing body of preclinical and clinical evidence supporting LM11A-31's potential to address multiple biological processes involved in Alzheimer's disease, including those associated with tau pathology and damage to brain cells and their connections.

C2N Diagnostics’ Role Providing Biopharma Clinical Research Services

C2N’s Biopharma Clinical Research Services used high-resolution mass spectrometry to measure levels of eMTBR-tau243 in the CSF samples collected from participants in the drug trial. The company offers highly sensitive mass spectrometry-based identification, quantification, and monitoring of proteins, protein fragments (peptides) and other biomolecules implicated in human neurological diseases. 

“It was a distinct pleasure working with Dr. Longo and his colleagues at PharmatrophiX on this important study. Our relationship with the PharmatrophiX team is a great example of how C2N's advanced biomarker technologies can help researchers better understand the biological effects of investigational Alzheimer's treatments,” said C2N CEO Joel Braunstein, MD. “By precisely measuring changes in a core tau pathology biomarker, we are helping advance the science needed to develop and evaluate new therapies. This is a nice case study in how our biomarker screening and monitoring tools save time and cost for Alzheimer’s and other related dementia clinical studies, while providing novel insights to the research and medical communities.”

Drug Offers Promise to Influencing Tau-Related Pathology

Currently approved disease-modifying Alzheimer's treatments work by removing amyloid plaques in the brain, which has been shown to slow cognitive decline in patients with early-stage disease. However, Alzheimer's disease involves multiple biological processes beyond amyloid, including the self-propagating buildup of harmful tau tangles and damage to brain cells and their connections.

PharmatrophiX is developing LM11A-31 as an investigational oral drug to address several of these processes through a different mechanism, including the prevention of the formation of abnormal tau. Researchers say the new findings provide additional evidence, along with its effects on the CSF total tau and plasma p-tau217 biomarkers, of its potential to influence tau-related pathology.

PharmatrophiX acknowledges support from the National Institutes on Aging, The Alzheimer’s Drug Development Foundation and the Alzheimer’s Association.

About PharmatrophiX

PharmatrophiX is a clinical-stage biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. PharmatrophiX was co-founded by Frank Longo, MD, PhD, and Anne Chun Longo. The company is advancing a pipeline of small-molecule drugs targeting p75 as well as the TrkB and TrkC receptors designed to prevent fundamental neurodegenerative mechanisms and to promote synaptic resilience with an emphasis on extensive collaboration with leading academic groups, disciplined clinical development and strategic collaboration.

About LM11A-31

PharmatrophiX’s lead asset is a first-in-class orally bioavailable, small molecule, (LM11A-31) targeting the p75 neurotrophin receptor. In published pre-clinical studies across multiple neurodegenerative disease models, LM11A-31 has been found to render synapses resilient to pathological forms of amyloid and tau, reduce the accumulation and spread of a broad range of pathological tau species, and reduce disease-associated microglial and astrocyte dysfunction. These activities are consistent with the known extensive overlap between the intracellular degenerative signaling networks regulated by the p75 receptor and degenerative networks upregulated in Alzheimer’s and related neurodegenerative diseases.

About the PharmatrophiX LM11A-31 Alzheimer’s Disease Program

PharmatrophiX has completed a Phase 2a safety- and biomarker-focused RCT study assessing mild-moderate Alzheimer’s disease in 242 enrolled participants, LM11A-31 demonstrated significant beneficial effects in five biomarker categories: structural MRI, FDG-PET, CSF synaptic and glial biomarkers, CSF proteomic modules with high significant weighting for synaptic proteins and plasma p-tau217. ADAS-cog13 and MMSE scores progressed significantly and as expected in the placebo group, with a 50% reduction of progression with both scores observed in the drug-treated group. A favorable safety profile was reported, and no treatment-related amyloid-related imaging abnormalities were reported (Shanks et al Nature Medicine 2024; CTAD 2025; NCT03069014; EudraCT 2018-001071-20). With encouraging clinical findings to date, and their consistency with extensive pre-clinical studies and underlying mechanisms, planning is underway for a phase 2b/3 Alzheimer’s disease trial.

For more information visit www.pharmatrophix.com

Media Contact
media@pharmatrophix.com

 
About C2N Diagnostics

C2N is a leading specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 200 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. Over 90,000 Precivity®-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.

The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation, Alzheimer’s Association and The Michael J. Fox Foundation. For more information visit http://www.c2n.com. 

Media Contact
info@c2n.com

Next
Next

C2N Diagnostics Expands Portfolio of Blood Tests with Next-Generation Brain Amyloid Assay for Clinical Researchers Studying Alzheimer’s Disease and Related Neurological Disorders